Curis Inc. of Cambridge has licensed its Hedgehog proteins and novel small molecule Hedgehog pathway agonists (activators) to Wyeth Pharmaceuticals, a division of N.J.-based Wyeth, for therapeutic ...
NEW YORK, May 23 (Reuters) - U.S. health regulators have delayed approval of Wyeth's experimental medicine for treating osteoporosis, requesting information about blood clots and stroke, the drug ...
July 20 (Reuters) - Wyeth Pharmaceuticals, a division of Wyeth , and Progenics Pharmaceuticals Inc. reported positive results from an early stage trial of a new oral formula of a drug candidate to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback